NA
ARKG icon

NewEdge Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

NewEdge Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1M Sell
23,840
-252
-1% -$8.03K ﹤0.01% 1659
2026
Q1 		$637K Buy
24,092
+12,202
+103% +$357K ﹤0.01% 1800
2025
Q4 		$344K Buy
11,890
+6,953
+141% +$209K ﹤0.01% 2218
2025
Q3 		$137K Sell
4,937
-318
-6% -$8.04K ﹤0.01% 2500
2025
Q2 		$128K Sell
5,255
-129
-2% -$2.83K ﹤0.01% 2341
2025
Q1 		$112K Buy
5,384
+1,780
+49% +$44.7K ﹤0.01% 2263
2024
Q4 		$84.9K Sell
3,604
-2,716
-43% -$66.8K ﹤0.01% 2330
2024
Q3 		$162K Sell
6,320
-1,368
-18% -$34.8K ﹤0.01% 2049
2024
Q2 		$181K Sell
7,688
-12,381
-62% -$312K ﹤0.01% 1953
2024
Q1 		$577K Sell
20,069
-1,952
-9% -$58.7K 0.01% 1258
2023
Q4 		$722K Sell
22,021
-8,181
-27% -$222K 0.01% 1101
2023
Q3 		$841K Sell
30,202
-6,631
-18% -$217K 0.01% 937
2023
Q2 		$1.26M Sell
36,833
-16,834
-31% -$529K 0.01% 763
2023
Q1 		$1.6M Sell
53,667
-3,932
-7% -$122K 0.02% 599
2022
Q4 		$883K Buy
57,599
+15,752
+38% +$500K 0.02% 551
2022
Q3 		$1.38M Buy
41,847
+3,110
+8% +$114K 0.02% 537
2022
Q2 		$1.22M Sell
38,737
-894
-2% -$31.3K 0.02% 597
2022
Q1 		$1.82M Sell
39,631
-3,422
-8% -$163K 0.03% 452
2021
Q4 		$2.64M Buy
43,053
+19,717
+84% +$1.36M 0.04% 374
2021
Q3 		$1.74M Buy
23,336
+1,443
+7% +$121K 0.04% 352
2021
Q2 		$2.02M Buy
21,893
+7,921
+57% +$673K 0.05% 313
2021
Q1 		$1.24M Buy
13,972
+987
+8% +$97.9K 0.04% 393
2020
Q4 		$1.21M Buy
12,985
+4,312
+50% +$344K 0.04% 373
2020
Q3 		$553K Buy
8,673
+4,342
+100% +$254K 0.02% 544
2020
Q2 		$226K Buy
+4,331
New +$186K 0.01% 743
2019
Q3 		– Sell
-7,743
Closed -$267K – 816
2019
Q2 		$267K Buy
7,743
+278
+4% +$8.91K 0.02% 550
2019
Q1 		$245K Buy
+7,465
New +$220K 0.02% 581
2018
Q4 		– Sell
-8,044
Closed -$269K – 628
2018
Q3 		$269K Buy
+8,044
New +$255K 0.02% 523

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

NewEdge Advisors's ARKG Position: Q2 2026 in Review

NewEdge Advisors reduced its ARK Genomic Revolution ETF (ARKG) stake by 1% in Q2 2026, selling an estimated $8.03K and leaving 23,840 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #1659.

NewEdge Advisors first reported a position in ARKG in Q3 2018 and has held it in 28 quarters since. The position peaked at $2.64M in Q4 2021. 272 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

  • NewEdge Advisors held 23,840 shares of ARK Genomic Revolution ETF worth $1M as of Q2 2026.
  • NewEdge Advisors sold 252 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $8.03K.
  • ARK Genomic Revolution ETF made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #1659 holding.
  • NewEdge Advisors first reported a position in ARK Genomic Revolution ETF in Q3 2018 and has held it in 28 quarters since.
  • NewEdge Advisors's ARK Genomic Revolution ETF position peaked at $2.64M in Q4 2021.
  • 272 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.